Rehan Aziz, MD

How to Identify and Treat Apathy and Late-Life Depression

October 1, 2022

Rehan Aziz, MD. associate program director, geriatric psychiatry fellowship program, Jersey Shore University Medical Center; associate professor of psychiatry and neurology, Hackensack Meridian School of Medicine, Nutley, NJ. Julia Cromwell, MD. Inpatient geriatric psychiatrist, Mass General Brigham Salem Hospital, Salem, MA.

Dr. Aziz and Dr. Cromwell, authors of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

We provide tips on distinguishing between apathy and depression, as well as recommendations on how to manage these disorders.

Harnessing Beneficial Drug Interactions

November 1, 2018

Rehan Aziz, MD and Chris Aiken, MD

Rehan Aziz, MD Associate Professor of Psychiatry and Neurology at Rutgers Robert Wood Johnson School of Medicine. Dr. Aziz has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Chris Aiken, MD Editor-in-Chief, The Carlat Psychiatry Report. Dr. Aiken has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

It’s nice when we can get our patients better with a single medication, but that’s not always possible. Sometimes the right combination of meds can do the trick, but studies of polypharmacy are scarce. In this article we dig through that research, small and limited as it is, to highlight a few useful combinations where the drug interaction can benefit your patient.

Opioids Not Superior to Other Medicines for Some Chronic Pain

October 1, 2018

Rehan Aziz, MD

Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Rising rates of opioid overdose deaths have sounded alarm bells over opioid prescribing practices for chronic pain. Unfortunately, and despite the absence of quality data on their risks vs benefits, long-term opioid management has remained a common approach to managing chronic musculoskeletal pain.

Sleep Apnea in Patients With Substance Use Disorders: A Primer

August 23, 2018

Rehan Aziz, MD

Rehan Aziz, MD Associate Professor of Psychiatry and Neurology, Rutgers University—Robert Wood Johnson Medical School Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are three types of sleep apnea: obstructive sleep apnea (OSA), central sleep apnea, and mixed. Of these, OSA is by far the most common, and that’s what we’ll focus on in this article. OSA is caused by excessive relaxation of the throat during sleep, which in some people causes enough obstruction to impede the flow of air.

Substance Use Disorders Are Under-Recognized in Patients With Diabetes

July 1, 2018

Rehan Aziz, MD

Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Type 2 diabetes (T2D) is a common condition with high treatment costs and significant morbidity and mortality. In 2015, an estimated 30.2 million American adults had T2D. Diabetes can be comorbid with other behavioral health disorders (BHDs), and this can lead to additional costs and increased morbidity and mortality risk.

Does Adolescent Vaping Lead to Cigarette Smoking?

March 1, 2018

Rehan Aziz, MD

Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Considering them less lethal than traditional cigarettes, many adolescents are turning to electronic cigarettes as a “safer” alternative to tobacco products.

Neurostimulation for Opioid Withdrawal Symptoms

January 1, 2018

Rehan Aziz, MD

Rehan Aziz, MD Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A challenging barrier for patients with opioid use disorders is the discomfort that can occur during the “induction phase” of their treatment, which is the period between discontinuation of opioids and initiation of medication-assisted therapy (MAT).